sucralfate

FDA Drug Profile — sucralfate, Sucralfate oral suspension

Drug Details

Generic Name
sucralfate
Brand Names
sucralfate, Sucralfate oral suspension
Application Number
ANDA212913
Sponsor
Mylan Pharmaceuticals Inc.
NDC Codes
3
Dosage Forms
SUSPENSION, TABLET
Routes
ORAL
Active Ingredients
SUCRALFATE

Indications and Usage

INDICATIONS AND USAGE Sucralfate tablets, USP are indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.